What's new

Human medicines European public assessment report (EPAR): Nuvaxovid, COVID-19 Vaccine (recombinant, adjuvanted), Date of authorisation: 20/12/2021, Revision: 18, Status: Authorised

Human medicines European public assessment report (EPAR): Nuvaxovid, COVID-19 Vaccine (recombinant, adjuvanted), Date of authorisation: 20/12/2021, Revision: 18, Status: Authorised

May 2, 2025 - 18:44
 0
Human medicines European public assessment report (EPAR): Nuvaxovid, COVID-19 Vaccine (recombinant, adjuvanted), Date of authorisation: 20/12/2021, Revision: 18, Status: Authorised
Human medicines European public assessment report (EPAR): Nuvaxovid, COVID-19 Vaccine (recombinant, adjuvanted), Date of authorisation: 20/12/2021, Revision: 18, Status: Authorised
Read More

Tags:

Previous Article

Airlines Are Counting on Premium Even More – and 3 Other Takeaways From Earnings...

Next Article

WHITE RABBIT is taking on the premium ambient biscuit aisle

Related Posts

Human medicines European public assessment report (EPAR): Segluromet, ertugliflozin,metformin hydrochloride, Date of authorisation: 23/03/2018, Revision: 9, Status: Authorised

Human medicines European public assessment report (EPAR...

May 2, 2025  0

Human medicines European public assessment report (EPAR): Duvyzat, givinostat, Status: Opinion

Human medicines European public assessment report (EPAR...

Apr 25, 2025  0

Industry annual bilateral meetings

Industry annual bilateral meetings

Apr 29, 2025  0